Annals of the rheumatic diseases
-
Randomized Controlled Trial
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.
To determine the efficacy of CP-690,550 in improving pain, function and health status in patients with moderate to severe active rheumatoid arthritis (RA) and an inadequate response to methotrexate or a tumour necrosis factor alpha inhibitor. ⋯ CP-690,550 was efficacious in improving the pain, function and health status of patients with RA, from week 1 to week 6.